HRP20160261T1 - Komplementarni antagonisti i njihova uporaba - Google Patents
Komplementarni antagonisti i njihova uporaba Download PDFInfo
- Publication number
- HRP20160261T1 HRP20160261T1 HRP20160261TT HRP20160261T HRP20160261T1 HR P20160261 T1 HRP20160261 T1 HR P20160261T1 HR P20160261T T HRP20160261T T HR P20160261TT HR P20160261 T HRP20160261 T HR P20160261T HR P20160261 T1 HRP20160261 T1 HR P20160261T1
- Authority
- HR
- Croatia
- Prior art keywords
- oligomer
- oligomer according
- nucleotides
- modified
- sugar part
- Prior art date
Links
- 230000000295 complement effect Effects 0.000 title claims 4
- 239000005557 antagonist Substances 0.000 title 1
- 125000003729 nucleotide group Chemical group 0.000 claims 7
- 239000002773 nucleotide Substances 0.000 claims 6
- 230000001684 chronic effect Effects 0.000 claims 3
- 230000003210 demyelinating effect Effects 0.000 claims 3
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims 1
- 208000006411 Hereditary Sensory and Motor Neuropathy Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 238000011529 RT qPCR Methods 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 210000003050 axon Anatomy 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 230000001351 cycling effect Effects 0.000 claims 1
- 206010061811 demyelinating polyneuropathy Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000021995 hereditary motor and sensory neuropathy Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000036546 leukodystrophy Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (14)
1. Jednolančani antisense oligomer duljine od 10 do 50 nukleotida koji ima graničnu nukleobaznu sekvenciju s bar 80% sekvencijske identičnosti s komplementarnom regijom nukleinske kiseline koja kodira KOMPLEMENTARNU KOMPONENTU 6 (C6) sekvence predstavljene SEQ ID NO: 1; oligomer sadrži najmanje jedan analog nukleotida a koji ima sposobnost reduciranja razine C6 mRNA ekspresije u sisavaca za najmanje 20% kako je određeno pomoću qPCR testa, naznačen time da je oligomer targetiran na nukleotide 112-152, 433-473, 546 -586, 706-746 ili 1015-1055 iz ATG start mjesta SEQ ID NO: 1.
2. Oligomer prema zahtjevu 1, naznačen time da oligomer nadalje sadrži barem jedno od modificirane internukleotide spojnice i modificirane nukleobaze.
3. Oligomer prema zahtjevu 1, naznačen time da je analog nukleotida modificirani šećerni dio odabran iz skupine koja se sastoji od: 2'-O-metoksietil modificirani šećerni dio, 2'-metoksi modificirani šećerni dio, 2'-O-alkil modificirani šećera dio i biciklički šećerni dio.
4. Oligomer prema zahtjevu 3, naznačen time da je biciklički šećerni dio monomer zaključane nukleinske kiseline (LNA).
5. Oligomer prema zahtjevu 2, naznačen time da je modificirana internukleotidna spojnica fosforotioatna internukleotidna spojnica.
6. Oligomer prema zahtjevu 2, naznačen time da je modificirana nukleobaza 5-metilcitozin.
7. Oligomer prema zahtjevu 1, naznačen time da je oligomer između 12 do 45 nukleotida duljine.
8. Oligomer prema zahtjevu 1, naznačen time da je oligomer između 10 do 18 nukleotida duljine.
9. Oligomer prema zahtjevu 1, naznačen time da je oligomer targetiran na nukleotide 132, 453, 566, 726 ili 1035 iz ATG start mjesta SEQ ID NO: 1.
10. Oligomer prema zahtjevu 1 ili 9, naznačen time da oligomer ima najmanje 90%, 96%, 97%, 98% ili 99% sekvencijske identičnosti s KOMPLEMENTARNOM KOMPONENTOM C6 sekvence predstavljene SEQ ID NO: 1.
11. Farmaceutski pripravak koji sadrži oligomer prema zahtjevu 1 ili 2 i farmaceutski prihvatljivo otapalo, sol ili pomoćno sredstvo.
12. Uporaba najmanje jednog oligomera prema zahtjevu 1 za proizvodnju lijeka za liječenje stanja koje zahtijeva regeneraciju aksona.
13. Uporaba najmanje jednog od oligomera prema zahtjevu 1 za proizvodnju lijeka za liječenje kroničnog demijelinizirajućeg stanja.
14. Uporaba prema zahtjevu 13, naznačena time da je kronično demijelinizirajuće stanje multipla skleroza, kronična demijelinacijska neuropatija, HMSN (CMT) tipa bolesti IA i IB, Alzheimerova bolest, Huntingtonova bolest, Charcot-Marie-Tooth bolest, amiotrofna lateralna skleroza (ALS), Guillain-Barre sindrom (GBS, također poznat kao akutna upalna demijelinacijska polineuropatija ili AIDP), leukodistrofija, ili Parkinsonova bolest.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7950108P | 2008-07-10 | 2008-07-10 | |
| PCT/NL2009/050418 WO2010005310A2 (en) | 2008-07-10 | 2009-07-10 | Complement antagonists and uses thereof |
| EP09788222.9A EP2320925B1 (en) | 2008-07-10 | 2009-07-10 | Complement antagonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160261T1 true HRP20160261T1 (hr) | 2016-06-03 |
Family
ID=41507609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160261TT HRP20160261T1 (hr) | 2008-07-10 | 2016-03-14 | Komplementarni antagonisti i njihova uporaba |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8703730B2 (hr) |
| EP (1) | EP2320925B1 (hr) |
| JP (1) | JP2011527568A (hr) |
| KR (1) | KR20110044983A (hr) |
| CN (2) | CN102149390A (hr) |
| AU (1) | AU2009270020B2 (hr) |
| CA (1) | CA2730203C (hr) |
| CY (1) | CY1117476T1 (hr) |
| DK (1) | DK2320925T3 (hr) |
| ES (1) | ES2566008T3 (hr) |
| HR (1) | HRP20160261T1 (hr) |
| HU (1) | HUE027169T2 (hr) |
| IL (1) | IL210506A (hr) |
| NZ (1) | NZ591057A (hr) |
| PL (1) | PL2320925T3 (hr) |
| SI (1) | SI2320925T1 (hr) |
| SM (1) | SMT201600098B (hr) |
| WO (1) | WO2010005310A2 (hr) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8097712B2 (en) | 2007-11-07 | 2012-01-17 | Beelogics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
| US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
| WO2011105900A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-alpha (c8-alpha) and uses thereof |
| WO2011105902A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-beta (c8-beta) and uses thereof |
| WO2011105901A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 9 (c9) and uses thereof |
| HUE033056T2 (hu) | 2010-03-08 | 2017-11-28 | Monsanto Technology Llc | Polinukleotid molekulák génszabályozáshoz növényekben |
| UA116088C2 (uk) | 2011-09-13 | 2018-02-12 | Монсанто Текнолоджи Ллс | Спосіб та композиція для боротьби з бур'янами (варіанти) |
| EP2756085B1 (en) | 2011-09-13 | 2019-03-20 | Monsanto Technology LLC | Methods and compositions for weed control |
| MX343071B (es) | 2011-09-13 | 2016-10-21 | Monsanto Technology Llc | Metodos y composiciones para el control de malezas. |
| WO2013040033A1 (en) | 2011-09-13 | 2013-03-21 | Monsanto Technology Llc | Methods and compositions for weed control |
| CA2848689A1 (en) | 2011-09-13 | 2013-03-21 | Monsanto Technology Llc | Methods and compositions for weed control targeting pds |
| US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
| US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
| US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
| CN103958686A (zh) | 2011-09-13 | 2014-07-30 | 孟山都技术公司 | 用于杂草控制的方法和组合物 |
| CN103958539B (zh) | 2011-09-13 | 2019-12-17 | 孟山都技术公司 | 用于杂草控制的方法和组合物 |
| ES2645927T3 (es) | 2011-09-13 | 2017-12-11 | Monsanto Technology Llc | Procedimientos y composiciones para el control de malezas |
| US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| AU2013243953A1 (en) * | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of nuclear proteins |
| SI2841578T1 (sl) | 2012-04-23 | 2017-12-29 | Biomarin Technologies B.V. | Rna modulirajoči oligonukleotidi z izboljšanimi karakteristikami za zdravljenje nevromuskularnih motenj |
| UY34822A (es) | 2012-05-24 | 2013-12-31 | Seeds Ltd Ab | Composiciones y métodos para silenciar la expresión genética |
| ES2763413T3 (es) | 2012-09-24 | 2020-05-28 | Seminis Vegetable Seeds Inc | Procedimientos y composiciones para prolongar la vida útil de productos vegetales |
| US10260089B2 (en) | 2012-10-29 | 2019-04-16 | The Research Foundation Of The State University Of New York | Compositions and methods for recognition of RNA using triple helical peptide nucleic acids |
| WO2014096958A1 (en) | 2012-11-02 | 2014-06-26 | Academisch Medisch Centrum | Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders |
| CN104837996A (zh) | 2012-11-15 | 2015-08-12 | 罗氏创新中心哥本哈根有限公司 | 抗apob反义缀合物化合物 |
| EP2941488B1 (en) | 2013-01-01 | 2023-03-22 | Monsanto Technology LLC | Methods of introducing dsrna to plant seeds for modulating gene expression |
| US10683505B2 (en) | 2013-01-01 | 2020-06-16 | Monsanto Technology Llc | Methods of introducing dsRNA to plant seeds for modulating gene expression |
| CN105188382B (zh) | 2013-01-15 | 2019-02-19 | 孟山都技术公司 | 用于植物害虫控制的方法和组合物 |
| CA2893801A1 (en) | 2013-01-30 | 2014-08-07 | F. Hoffmann-La Roche Ag | Lna oligonucleotide carbohydrate conjugates |
| CN105263329B (zh) | 2013-03-13 | 2020-09-18 | 孟山都技术公司 | 用于杂草控制的方法和组合物 |
| US10609930B2 (en) | 2013-03-13 | 2020-04-07 | Monsanto Technology Llc | Methods and compositions for weed control |
| US20140283211A1 (en) | 2013-03-14 | 2014-09-18 | Monsanto Technology Llc | Methods and Compositions for Plant Pest Control |
| US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
| EP3608412A3 (en) | 2013-07-19 | 2020-04-08 | Monsanto Technology LLC | Compositions and methods for controlling leptinotarsa |
| US9850496B2 (en) | 2013-07-19 | 2017-12-26 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
| HUE045109T2 (hu) * | 2013-09-13 | 2019-12-30 | Ionis Pharmaceuticals Inc | A B-komplementfaktor modulátorai |
| CA2929533C (en) | 2013-11-04 | 2023-06-06 | Monsanto Technology Llc | Compositions and methods for controlling arthropod parasite and pest infestations |
| UA119253C2 (uk) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Спосіб боротьби із вірусом у кліща varroa та у бджіл |
| CN105979770B (zh) | 2014-01-15 | 2019-07-05 | 孟山都技术公司 | 用于使用epsps多核苷酸的杂草控制的方法和组合物 |
| US11091770B2 (en) | 2014-04-01 | 2021-08-17 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
| PL3137596T3 (pl) | 2014-05-01 | 2019-11-29 | Ionis Pharmaceuticals Inc | Kompozycja i sposoby modulowania ekspresji czynnika b dopełniacza |
| WO2015200223A1 (en) | 2014-06-23 | 2015-12-30 | Monsanto Technology Llc | Compositions and methods for regulating gene expression via rna interference |
| US11807857B2 (en) | 2014-06-25 | 2023-11-07 | Monsanto Technology Llc | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
| RU2754955C2 (ru) | 2014-07-29 | 2021-09-08 | Монсанто Текнолоджи Ллс | Композиции и способы борьбы с насекомыми-вредителями |
| PL3233912T3 (pl) | 2014-12-19 | 2021-12-27 | Regenesance B.V. | Przeciwciała, które wiążą ludzkie c6 oraz ich zastosowania |
| WO2016118007A1 (en) | 2015-01-21 | 2016-07-28 | Regenesance B.V. | Means and methods for counteracting complement-mediated hemolytic anemia |
| MX2017009521A (es) | 2015-01-22 | 2018-11-09 | Monsanto Technology Llc | Composiciones y métodos para controlar leptinotarsa. |
| US10883103B2 (en) | 2015-06-02 | 2021-01-05 | Monsanto Technology Llc | Compositions and methods for delivery of a polynucleotide into a plant |
| AU2016270913A1 (en) | 2015-06-03 | 2018-01-04 | Monsanto Technology Llc | Methods and compositions for introducing nucleic acids into plants |
| MA43072A (fr) * | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| CN109312344A (zh) | 2016-01-26 | 2019-02-05 | 孟山都技术公司 | 用于控制昆虫害虫的组合物和方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030096775A1 (en) * | 2001-10-23 | 2003-05-22 | Isis Pharmaceuticals Inc. | Antisense modulation of complement component C3 expression |
| EP1560931B1 (en) * | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| AU2005248147A1 (en) * | 2004-05-11 | 2005-12-08 | Alphagen Co., Ltd. | Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
| NZ567483A (en) * | 2005-11-04 | 2012-04-27 | Genentech Inc | Use of complement pathway inhibitors to treat ocular diseases |
| EP1966379B1 (en) | 2005-12-22 | 2010-04-28 | OPKO Ophthalmics, LLC | Compositions and methods for regulating complement system |
| PT3028716T (pt) * | 2006-10-10 | 2020-11-23 | Regenesance B V | Inibição do complemento para regeneração nervosa melhorada |
-
2009
- 2009-07-10 PL PL09788222T patent/PL2320925T3/pl unknown
- 2009-07-10 CN CN2009801354301A patent/CN102149390A/zh active Pending
- 2009-07-10 CA CA2730203A patent/CA2730203C/en active Active
- 2009-07-10 HU HUE09788222A patent/HUE027169T2/en unknown
- 2009-07-10 AU AU2009270020A patent/AU2009270020B2/en active Active
- 2009-07-10 WO PCT/NL2009/050418 patent/WO2010005310A2/en active Application Filing
- 2009-07-10 CN CN201310576286.3A patent/CN103740713A/zh active Pending
- 2009-07-10 DK DK09788222.9T patent/DK2320925T3/en active
- 2009-07-10 SI SI200931393A patent/SI2320925T1/sl unknown
- 2009-07-10 US US13/003,062 patent/US8703730B2/en active Active
- 2009-07-10 KR KR1020117001948A patent/KR20110044983A/ko not_active Application Discontinuation
- 2009-07-10 EP EP09788222.9A patent/EP2320925B1/en active Active
- 2009-07-10 JP JP2011517368A patent/JP2011527568A/ja active Pending
- 2009-07-10 NZ NZ591057A patent/NZ591057A/xx unknown
- 2009-07-10 ES ES09788222.9T patent/ES2566008T3/es active Active
-
2011
- 2011-01-06 IL IL210506A patent/IL210506A/en active IP Right Grant
-
2014
- 2014-03-12 US US14/206,022 patent/US9089555B2/en active Active
-
2016
- 2016-03-14 HR HRP20160261TT patent/HRP20160261T1/hr unknown
- 2016-03-23 CY CY20161100247T patent/CY1117476T1/el unknown
- 2016-04-05 SM SM201600098T patent/SMT201600098B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL210506A0 (en) | 2011-03-31 |
| JP2011527568A (ja) | 2011-11-04 |
| IL210506A (en) | 2015-06-30 |
| NZ591057A (en) | 2012-11-30 |
| US8703730B2 (en) | 2014-04-22 |
| AU2009270020B2 (en) | 2014-09-25 |
| PL2320925T3 (pl) | 2016-06-30 |
| AU2009270020A1 (en) | 2010-01-14 |
| ES2566008T3 (es) | 2016-04-08 |
| CN103740713A (zh) | 2014-04-23 |
| US9089555B2 (en) | 2015-07-28 |
| CY1117476T1 (el) | 2017-04-26 |
| AU2009270020A2 (en) | 2011-01-27 |
| CA2730203A1 (en) | 2010-01-14 |
| WO2010005310A3 (en) | 2010-04-15 |
| HUE027169T2 (en) | 2016-10-28 |
| KR20110044983A (ko) | 2011-05-03 |
| SMT201600098B (it) | 2016-04-29 |
| CN102149390A (zh) | 2011-08-10 |
| DK2320925T3 (en) | 2016-03-21 |
| WO2010005310A2 (en) | 2010-01-14 |
| US20150211003A9 (en) | 2015-07-30 |
| US20110171176A1 (en) | 2011-07-14 |
| CA2730203C (en) | 2016-12-13 |
| SI2320925T1 (sl) | 2016-05-31 |
| EP2320925B1 (en) | 2015-12-23 |
| US20140301982A1 (en) | 2014-10-09 |
| EP2320925A2 (en) | 2011-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160261T1 (hr) | Komplementarni antagonisti i njihova uporaba | |
| EP3325097B1 (en) | Compositions and agents against hepatitis b virus and uses thereof | |
| HRP20201200T1 (hr) | OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK | |
| CA3004799C (en) | Oligonucleotides for inducing paternal ube3a expression | |
| JP7406793B2 (ja) | ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法 | |
| JP2021513861A (ja) | Ｃａｍｋ２ｄアンチセンスオリゴヌクレオチドおよびその使用 | |
| JP2016533717A5 (hr) | ||
| JP2015518711A5 (hr) | ||
| JP6752151B2 (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| JP2015523853A5 (hr) | ||
| HRP20220379T1 (hr) | Antisense oligonukleotidi korisni u liječenju pompeove bolesti | |
| US11732262B2 (en) | Use of FUBP1 inhibitors for treating hepatitis B virus infection | |
| JP2016513976A5 (hr) | ||
| JP2016520310A5 (hr) | ||
| JP2009512673A5 (hr) | ||
| US20220213484A1 (en) | Angptl2 antisense oligonucleotides and uses thereof | |
| JP2023506546A (ja) | Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用 | |
| JP2023506540A (ja) | Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用 | |
| EP4353823A1 (en) | Inhibitors of micro-rna 22 | |
| WO2018047148A1 (en) | Compounds for the inhibition of mirna | |
| WO2021231211A1 (en) | Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same | |
| WO2016188729A1 (en) | Methods for the therapy of protein-misfolding-diseases | |
| EP4150085A1 (en) | Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same | |
| JP2023506547A (ja) | Ｂ型肝炎ウイルス感染を処置するためのｃｏｐｓ３阻害剤の使用 | |
| EP4150084A1 (en) | Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same |